Strong Enrollment Momentum Reported in Ph 3 OVATION 3 Trial of IMNN-001 in Advanced Ovarian Cancer August 5, 2026
Preliminary data from Ph 2 MRD translational clinical trial of IMNN-001 + SOC N/ACT & bevacizumab in women with 1L advanced ovarian cancer announced July 28, 2026
Independent DMC recommended continuation of Ph 3 OVATION 3 trial of IMNN-001 + SOC neoadjuvant and adjuvant chemo in 1L ovarian cancer June 30, 2026
FAILED TRIAL: Ph 2 DOVACC study evaluating UV1 in BRCAwt platinum sensitive recurrent ovarian cancer did not meet primary endpoint of PFS improvement June 30, 2026
Key Manufacturing and IND Preparation Milestones for ERNA-101 Toward First-in-Human Clinical Development Successfully Completed June 2, 2026
First Patient Dosed in ASPENOVA Ph 3 Trial of Azenosertib in Patients with Cyclin E1-Positive Platinum-Resistant Ovarian Cancer May 12, 2026
50% ORR Announced in Recurrent Ovarian Cancer Ph 2 Trial of Ampligen, Pembrolizumab and Cisplatin May 12, 2026
Updated Positive Survival Observations from Ph 1 Trial of Lira-cel Ovarian Cancer CAR-T Therapy Reported May 12, 2026
Clinical Trial Application approved for CryptiVax-1001 OVACT trial in Advanced High-Grade Serous Ovarian Cancer April 28, 2026
FDA Fast Track Designation for Lunresertib in Combination with Zedoresertib for Genomic-Defined Platinum-Resistant Ovarian Cancer April 21, 2026
Safety and Tolerability of Rinatabart Sesutecan (Rina-S®) in Combination with Bevacizumab in Advanced Ovarian Cancer Presented April 21, 2026
Ph 2 Data for Mirvetuximab Soravtansine-gynx (ELAHERE®) in Platinum‑Sensitive Ovarian Cancer (PSOC) Presented April 21, 2026
Results Announced from Ph 2 SKB264-II-06/MK-2870-002 Study of Sacituzumab Tirumotecan (Sac-TMT) in ovarian cancer cohort and the cervical cancer cohorts April 21, 2026
Mocertatug rezetecan achieved confirmed ORR of 62% in platinum-resistant ovarian cancer (PROC) and 67% in recurrent/advanced endometrial cancer in BEHOLD-1 study April 15, 2026
Gilead to Acquire Tubulis Adding ADC and Next Gen Platform to Further Strengthen Oncology Pipeline April 15, 2026
2-Year Median Follow-Up Data on AVMAPKI® FAKZYNJA® Combination Therapy in Recurrent Low-Grade Serous Ovarian Cancer presented April 15, 2026
Results from Ph 2 IMGN853-0420 trial show ORR of 62.7% with ELAHERE + chemo followed by ELAHERE monotherapy in patients with ≥50% FRα-expressing PSOC April 15, 2026
CTIM-76 Receives FDA Fast Track Designation for the Treatment of Platinum-Resistant Ovarian Cancer April 7, 2026
